Results 1 to 10 of about 182 (124)
Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features [PDF]
Clinical and Translational Allergy, 2022 Background Nonsteroidal anti‐inflammatory drugs (NSAIDs) are frequently avoided in mastocytosis, because of a potential increased risk for drug hypersensitivity reactions (DHRs) due to inhibition of cyclo‐oxygenase (COX), subsequent depletion of ...
Tiago Azenha Rama +9 more
doaj +2 more sources
Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review [PDF]
Clinical and Translational Allergy, 2023 Background Mastocytosis manifests with multisystemic symptoms, often involving the nervous system. Numerous cognitive, neuropsychiatric and neurological alterations have been reported in multiple observational studies.
Elena Sagües‐Sesé +2 more
doaj +2 more sources
Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap [PDF]
Frontiers in Pharmacology, 2020 Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa +1 more
doaj +2 more sources
Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas [PDF]
Frontiers in Oncology, 2021 Human WHO grade 1 meningiomas are generally considered benign tumors; despite this, they account for ≈50% of all recurrent meningiomas. Currently, limited data exist about the mutational profiles of grade 1 meningiomas and patient outcome.
María González-Tablas +28 more
doaj +2 more sources
Insights in Anaphylaxis and Clonal Mast Cell Disorders [PDF]
Frontiers in Immunology, 2017 The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might ...
David González-de-Olano +1 more
doaj +2 more sources
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal [PDF]
HemaSphere, 2021 Mastocytosis is a hematologic neoplasm characterized by expansion and focal accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone marrow (BM), spleen, liver, and gastrointestinal tract.
Peter Valent +39 more
doaj +2 more sources
Revista Alergia México, 2015 Mastocytosis is one of the eight subcategories of the myeloproliferative neoplasms of the classification of lymphoid and hematopoietic tissues’ tumors of 2008 of World Health Organization; it is an heterogeneous group of myeloproliferative diseases ...
Sandra Nora González-Díaz +3 more
doaj +3 more sources
Pregnancy and Delivery in Patients with Mastocytosis Treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). [PDF]
PLoS ONE, 2016 OBJECTIVE:To present current guidelines regarding treatment of mastocytosis in pregnancy on the example of observed patients. DESIGN:Case control national study. SETTING:Polish Center of the European Competence Network on Mastocytosis (ECNM).
Katarzyna Ciach +9 more
doaj +2 more sources
Mastocitosis: urticaria pigmentosa
Revista de Ciencias Médicas de Pinar del Río, 2015 La mastocitosis es una enfermedad rara. Se caracteriza por una proliferación benigna o en raras ocasiones maligna de mastocitos en los tejidos. Puede producir alteraciones tanto sistémicas como cutáneas.
Pedro Antonio Díaz Llanio +4 more
doaj +1 more source
Revista Cubana de Hematología, Inmunología y Hemoterapia, 2011 Las mastocitosis están incluidas dentro del grupo de "enfermedades raras" debido a su baja frecuencia. Se caracterizan por el crecimiento y acumulación de causa desconocida de mastocitos en piel y otros órganos. Las manifestaciones clínicas se deben a la
Catalino R Ustáriz-García
doaj +1 more source